Clinically significant antibiotic resistance has evolved against virtually every antibiotic deployed. Yet the development of new classes of antibiotics has lagged far behind our growing need for such drugs. Rather than focusing on therapeutics that target in vitro viability, much like conventional antibiotics, an alternative approach is to target functions essential for infection, such as virulence factors required to cause host damage and disease. This approach has several potential advantages including expanding the repertoire of bacterial targets, preserving the host endogenous microbiome, and exerting less selective pressure, which may result in decreased resistance. We review new approaches to targeting virulence, discuss their advantages and disadvantages, and propose that in addition to targeting virulence, new antimicrobial development strategies should be expanded to include targeting bacterial gene functions that are essential for in vivo viability. We highlight both new advances in identifying these functions and prospects for antimicrobial discovery targeting this unexploited area.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Palumbi, S.R. Humans as the world's greatest evolutionary force. Science 293, 1786–1790 (2001).
Young, J.A. & Collier, R.J. Anthrax toxin: receptor-binding, internalization, pore formation, and translocation. Annu. Rev. Biochem. 76, 243–265 (2007).
Boyden, E.D. & Dietrich, W.F. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat. Genet. 38, 240–244 (2006).
Duesbery, N.S. et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280, 734–737 (1998).
Vitale, G. et al. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem. Biophys. Res. Commun. 248, 706–711 (1998).
Panchal, R.G. et al. Chemical genetic screening identifies critical pathways in anthrax lethal toxin-induced pathogenesis. Chem. Biol. 14, 245–255 (2007).
During, R.L. et al. Anthrax lethal toxin paralyzes actin-based motility by blocking Hsp27 phosphorylation. EMBO J. 26, 2240–2250 (2007).
Rainey, G.J. & Young, J.A. Antitoxins: novel strategies to target agents of bioterrorism. Nat. Rev. Microbiol. 2, 721–726 (2004).
Shoop, W.L. et al. Anthrax lethal factor inhibition. Proc. Natl. Acad. Sci. USA 102, 7958–7963 (2005).
Turk, B.E. et al. The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nat. Struct. Mol. Biol. 11, 60–66 (2004).
Krantz, B.A. et al. A phenylalanine clamp catalyzes protein translocation through the anthrax toxin pore. Science 309, 777–781 (2005).
Artenstein, A.W. et al. Chloroquine enhances survival in Bacillus anthracis intoxication. J. Infect. Dis. 190, 1655–1660 (2004).
Sanchez, A.M. et al. Amiodarone and bepridil inhibit anthrax toxin entry into host cells. Antimicrob. Agents Chemother 51, 2403–2411 (2007).
Moayeri, M., Wiggins, J.F., Lindeman, R.E. & Leppla, S.H. Cisplatin inhibition of anthrax lethal toxin. Antimicrob. Agents Chemother. 50, 2658–2665 (2006).
Ma, T. et al. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J. Clin. Invest. 110, 1651–1658 (2002).
King, C.Y. & Barriere, S.L. Analysis of the in vitro interaction between vancomycin and cholestyramine. Antimicrob. Agents Chemother. 19, 326–327 (1981).
Galan, J.E. & Wolf-Watz, H. Protein delivery into eukaryotic cells by type III secretion machines. Nature 444, 567–573 (2006).
Kauppi, A.M., Nordfelth, R., Uvell, H., Wolf-Watz, H. & Elofsson, M. Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. Chem. Biol. 10, 241–249 (2003).
Nordfelth, R., Kauppi, A.M., Norberg, H.A., Wolf-Watz, H. & Elofsson, M. Small-molecule inhibitors specifically targeting type III secretion. Infect. Immun. 73, 3104–3114 (2005).
Muschiol, S. et al. A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc. Natl. Acad. Sci. USA 103, 14566–14571 (2006).
Bailey, L. et al. Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle. FEBS Lett. 581, 587–595 (2007).
Hudson, D.L. et al. Inhibition of type III secretion in Salmonella enterica serovar Typhimurium by small-molecule inhibitors. Antimicrob. Agents Chemother 51, 2631–2635 (2007).
Stevens, D.L., Gibbons, A.E., Bergstrom, R. & Winn, V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J. Infect. Dis. 158, 23–28 (1988).
Miller, M.B. & Bassler, B.L. Quorum sensing in bacteria. Annu. Rev. Microbiol. 55, 165–199 (2001).
Parsek, M.R., Val, D.L., Hanzelka, B.L., Cronan, J.E. Jr. & Greenberg, E.P. Acyl homoserine-lactone quorum-sensing signal generation. Proc. Natl. Acad. Sci. USA 96, 4360–4365 (1999).
Dong, Y.H., Xu, J.L., Li, X.Z. & Zhang, L.H. AiiA, an enzyme that inactivates the acylhomoserine lactone quorum-sensing signal and attenuates the virulence of Erwinia carotovora. Proc. Natl. Acad. Sci. USA 97, 3526–3531 (2000).
Dong, Y.H. et al. Quenching quorum-sensing-dependent bacterial infection by an N-acyl homoserine lactonase. Nature 411, 813–817 (2001).
Yang, F. et al. Quorum quenching enzyme activity is widely conserved in the sera of mammalian species. FEBS Lett. 579, 3713–3717 (2005).
Draganov, D.I. et al. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res. 46, 1239–1247 (2005).
Muh, U. et al. Novel Pseudomonas aeruginosa quorum-sensing inhibitors identified in an ultra-high-throughput screen. Antimicrob. Agents Chemother. 50, 3674–3679 (2006).
Geske, G.D., Wezeman, R.J., Siegel, A.P. & Blackwell, H.E. Small molecule inhibitors of bacterial quorum sensing and biofilm formation. J. Am. Chem. Soc. 127, 12762–12763 (2005).
Smith, K.M., Bu, Y. & Suga, H. Induction and inhibition of Pseudomonas aeruginosa quorum sensing by synthtic autoinducer analogs. Chem. Biol. 10, 81–89 (2003).
Givskov, M. et al. Eukaryotic interference with homoserine lactone-mediated prokaryotic signalling. J. Bacteriol. 178, 6618–6622 (1996).
Manefield, M. et al. Halogenated furanones inhibit quorum sensing through accelerated LuxR turnover. Microbiology 148, 1119–1127 (2002).
Manefield, M., Welch, M., Givskov, M., Salmond, G.P. & Kjelleberg, S. Halogenated furanones from the red alga, Delisea pulchra, inhibit carbapenem antibiotic synthesis and exoenzyme virulence factor production in the phytopathogen Erwinia carotovora. FEMS Microbiol. Lett. 205, 131–138 (2001).
Hentzer, M. et al. Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. Microbiology 148, 87–102 (2002).
Hentzer, M. et al. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J. 22, 3803–3815 (2003).
Wu, H. et al. Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. J. Antimicrob. Chemother. 53, 1054–1061 (2004).
Yates, E.A. et al. N-acylhomoserine lactones undergo lactonolysis in a pH-, temperature-, and acyl chain length-dependent manner during growth of Yersinia pseudotuberculosis and Pseudomonas aeruginosa. Infect. Immun. 70, 5635–5646 (2002).
Muh, U. et al. A structurally unrelated mimic of a Pseudomonas aeruginosa acyl-homoserine lactone quorum-sensing signal. Proc. Natl. Acad. Sci. USA 103, 16948–16952 (2006).
Lyon, G.J., Wright, J.S., Christopoulos, A., Novick, R.P. & Muir, T.W. Reversible and specific extracellular antagonism of receptor-histidine kinase signaling. J. Biol. Chem. 277, 6247–6253 (2002).
Mayville, P. et al. Structure-activity analysis of synthetic autoinducing thiolactone peptides from Staphylococcus aureus responsible for virulence. Proc. Natl. Acad. Sci. USA 96, 1218–1223 (1999).
Wright, J.S. III, Jin, R. & Novick, R.P. Transient interference with staphylococcal quorum sensing blocks abscess formation. Proc. Natl. Acad. Sci. USA 102, 1691–1696 (2005).
Hung, D.T., Shakhnovich, E.A., Pierson, E. & Mekalanos, J.J. Small-molecule inhibitor of Vibrio cholerae virulence and intestinal colonization. Science 310, 670–674 (2005).
Gauthier, A. et al. Transcriptional inhibitor of virulence factors in enteropathogenic Escherichia coli. Antimicrob. Agents Chemother. 49, 4101–4109 (2005).
Sauer, F.G. et al. Chaperone-assisted pilus assembly and bacterial attachment. Curr. Opin. Struct. Biol. 10, 548–556 (2000).
Svensson, A. et al. Design and evaluation of pilicides: potential novel antibacterial agents directed against uropathogenic Escherichia coli. ChemBioChem 2, 915–918 (2001).
Pinkner, J.S. et al. Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc. Natl. Acad. Sci. USA 103, 17897–17902 (2006).
Lee, Y.M., Almqvist, F. & Hultgren, S.J. Targeting virulence for antimicrobial chemotherapy. Curr. Opin. Pharmacol. 3, 513–519 (2003).
Sassetti, C.M. & Rubin, E.J. Genetic requirements for mycobacterial survival during infection. Proc. Natl. Acad. Sci. USA 100, 12989–12994 (2003).
MacRae, C.A. & Peterson, R.T. Zebrafish-based small molecule discovery. Chem. Biol. 10, 901–908 (2003).
Peterson, R.T. et al. Chemical suppression of a genetic mutation in a zebrafish model of aortic coarctation. Nat. Biotechnol. 22, 595–599 (2004).
Stern, H.M. et al. Small molecules that delay S phase suppress a zebrafish bmyb mutant. Nat. Chem. Biol. 1, 366–370 (2005).
Davis, J.M. et al. Real-time visualization of Mycobacterium-macrophage interactions leading to initiation of granuloma formation in zebrafish embryos. Immunity 17, 693–702 (2002).
Neely, M.N., Pfeifer, J.D. & Caparon, M. Streptococcus-zebrafish model of bacterial pathogenesis. Infect. Immun. 70, 3904–3914 (2002).
van der Sar, A.M. et al. Zebrafish embryos as a model host for the real time analysis of Salmonella typhimurium infections. Cell. Microbiol. 5, 601–611 (2003).
Mukhopadhyay, A. & Peterson, R.T. Fishing for new antimicrobials. Curr. Opin. Chem. Biol. 10, 327–333 (2006).
Moy, T.I. et al. Identification of novel antimicrobials using a live-animal infection model. Proc. Natl. Acad. Sci. USA 103, 10414–10419 (2006).
Payne, D.J., Gwynn, M.N., Holmes, D.J. & Pompliano, D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29–40 (2007).
Lipinski, C.A., Lombardo, F., Dominy, B.W. & Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3–26 (2001).
Schreiber, S.L. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287, 1964–1969 (2000).
Sarac, M.S., Peinado, J.R., Leppla, S.H. & Lindberg, I. Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo. Infect. Immun. 72, 602–605 (2004).
We thank E.J. Rubin, J.E. Gomez and S.A. Stanley for helpful discussions and critical reading of this manuscript and J.S.W. Lee for assistance in preparing figures.
The authors declare no competing financial interests.
About this article
Cite this article
Clatworthy, A., Pierson, E. & Hung, D. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol 3, 541–548 (2007). https://doi.org/10.1038/nchembio.2007.24
Protein–protein interaction prediction based on ordinal regression and recurrent convolutional neural networks
BMC Bioinformatics (2021)
Discovery of uncompetitive inhibitors of SapM that compromise intracellular survival of Mycobacterium tuberculosis
Scientific Reports (2021)
Heterologous expression of AHL lactonase AiiK by Lactobacillus casei MCJΔ1 with great quorum quenching ability against Aeromonas hydrophila AH-1 and AH-4
Microbial Cell Factories (2020)
BMC Bioinformatics (2020)
Scientific Reports (2020)